4-aminopyridine has been researched along with Demyelinating Diseases in 21 studies
Demyelinating Diseases: Diseases characterized by loss or dysfunction of myelin in the central or peripheral nervous system.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The model of demyelination was carried out by the administration of cuprizone to the drinking water of the experimental mice." | 1.62 | Neuroprotective effect of newly synthesized 4-aminopyridine derivatives on cuprizone-induced demyelination in mice-a behavioral and immunohistochemical study. ( Danchev, N; Kostadinova, I; Landzhov, B; Marinov, L; Vezenkov, L, 2021) |
| "Central nervous system (CNS) demyelination represents the pathological hallmark of multiple sclerosis (MS) and contributes to other neurological conditions." | 1.48 | Development of a PET radioligand for potassium channels to image CNS demyelination. ( Basuli, F; Bezanilla, F; Brugarolas, P; Caprariello, AV; Chen, CT; Cheng, SH; DeJesus, O; Freifelder, R; Herscovitch, P; Lacroix, JJ; Miller, RH; Murali, D; Popko, B; Reich, DS; Sánchez-Rodríguez, JE; Swenson, RE; Tsai, HM; Zhang, X, 2018) |
| "This demyelination phenomenon exposed a subclass of voltage-gated potassium channels (K(v)1." | 1.36 | Compression induces acute demyelination and potassium channel exposure in spinal cord. ( Cheng, JX; Fu, Y; Li, J; Nauman, E; Ouyang, H; Shi, R; Sun, W, 2010) |
| "In cuprizone-induced demyelination, spontaneous remyelination occurs after the cessation of cuprizone diet." | 1.32 | K+ channel blockade impairs remyelination in the cuprizone model. ( Bacia, A; Soliven, B; Wollmann, R, 2004) |
| "To examine the action(s) of 4-AP in demyelinating disorders, the drug was administered at clinical doses, both in vivo and in vitro, to rat dorsal column axons which had been experimentally demyelinated by the intraspinal injection of ethidium bromide." | 1.31 | Effects of 4-aminopyridine on demyelinated axons, synapses and muscle tension. ( Felts, PA; John, GR; Smith, KJ, 2000) |
| "After demyelination by intraneural injection of lysolecithin, and during remyelination, the subcellular distributions of Kv1." | 1.30 | Potassium channel distribution, clustering, and function in remyelinating rat axons. ( Ellisman, MH; Levinson, SR; Rasband, MN; Schachner, M; Schwarz, TL; Shrager, P; Trimmer, JS, 1998) |
| "The demyelination was caused by intrathecal injection of diphtheria toxin, 6-9 days previously." | 1.28 | Ectopic activity in demyelinated spinal root axons of the rat. ( Baker, M; Bostock, H, 1992) |
| "In five rats with demyelination, slowed conduction velocity through the lesion was partially reversed at dose levels of 5." | 1.27 | Effects of 4-aminopyridine in experimental CNS demyelination. ( Kaji, R; Sumner, AJ, 1988) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 3 (14.29) | 18.7374 |
| 1990's | 7 (33.33) | 18.2507 |
| 2000's | 4 (19.05) | 29.6817 |
| 2010's | 5 (23.81) | 24.3611 |
| 2020's | 2 (9.52) | 2.80 |
| Authors | Studies |
|---|---|
| Al-Sabi, A | 1 |
| Daly, D | 1 |
| Hoefer, P | 1 |
| Kinsella, GK | 1 |
| Metais, C | 1 |
| Pickering, M | 1 |
| Herron, C | 1 |
| Kaza, SK | 1 |
| Nolan, K | 1 |
| Dolly, JO | 1 |
| Sun, Y | 3 |
| Guehl, NJ | 3 |
| Zhou, YP | 3 |
| Takahashi, K | 3 |
| Belov, V | 3 |
| Dhaynaut, M | 3 |
| Moon, SH | 3 |
| El Fakhri, G | 3 |
| Normandin, MD | 3 |
| Brugarolas, P | 4 |
| Kostadinova, I | 1 |
| Landzhov, B | 1 |
| Marinov, L | 1 |
| Vezenkov, L | 1 |
| Danchev, N | 1 |
| Sánchez-Rodríguez, JE | 1 |
| Tsai, HM | 1 |
| Basuli, F | 1 |
| Cheng, SH | 1 |
| Zhang, X | 1 |
| Caprariello, AV | 1 |
| Lacroix, JJ | 1 |
| Freifelder, R | 1 |
| Murali, D | 1 |
| DeJesus, O | 1 |
| Miller, RH | 1 |
| Swenson, RE | 1 |
| Chen, CT | 1 |
| Herscovitch, P | 1 |
| Reich, DS | 1 |
| Bezanilla, F | 1 |
| Popko, B | 1 |
| Lim, JH | 1 |
| Muguet-Chanoit, AC | 1 |
| Smith, DT | 1 |
| Laber, E | 1 |
| Olby, NJ | 1 |
| Ouyang, H | 1 |
| Sun, W | 2 |
| Fu, Y | 1 |
| Li, J | 1 |
| Cheng, JX | 1 |
| Nauman, E | 1 |
| Shi, R | 2 |
| Noble, M | 1 |
| Bacia, A | 1 |
| Wollmann, R | 1 |
| Soliven, B | 1 |
| Hayes, KC | 1 |
| Sears, TA | 1 |
| Bostock, H | 2 |
| Russell, JW | 1 |
| Windebank, AJ | 1 |
| Harper, CM | 1 |
| Felts, PA | 2 |
| Smith, KJ | 3 |
| Tamura, R | 1 |
| Mano, Y | 1 |
| Takayanagi, T | 1 |
| Mayer, RF | 1 |
| Bergin, PS | 1 |
| Miller, DH | 1 |
| Hirsch, NP | 1 |
| Murray, NM | 1 |
| Kapoor, R | 1 |
| Li, YG | 1 |
| Rasband, MN | 1 |
| Trimmer, JS | 1 |
| Schwarz, TL | 1 |
| Levinson, SR | 1 |
| Ellisman, MH | 1 |
| Schachner, M | 1 |
| Shrager, P | 1 |
| John, GR | 1 |
| Baker, M | 1 |
| Kaji, R | 1 |
| Sumner, AJ | 1 |
| Targ, EF | 1 |
| Kocsis, JD | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| [NCT00004939] | Phase 3 | 34 participants | Interventional | 1996-08-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
3 reviews available for 4-aminopyridine and Demyelinating Diseases
| Article | Year |
|---|---|
Potassium channel blockers as an effective treatment to restore impulse conduction in injured axons.
Topics: 4-Aminopyridine; Animals; Axons; Demyelinating Diseases; Humans; Neural Conduction; Potassium Channe | 2011 |
The possible role of myelin destruction as a precipitating event in Alzheimer's disease.
Topics: 4-Aminopyridine; Alzheimer Disease; Animals; Antibodies; Central Nervous System; Demyelinating Disea | 2004 |
The use of 4-aminopyridine (fampridine) in demyelinating disorders.
Topics: 4-Aminopyridine; Animals; Clinical Trials as Topic; Demyelinating Diseases; Humans | 2004 |
2 trials available for 4-aminopyridine and Demyelinating Diseases
| Article | Year |
|---|---|
Potassium channel antagonists 4-aminopyridine and the T-butyl carbamate derivative of 4-aminopyridine improve hind limb function in chronically non-ambulatory dogs; a blinded, placebo-controlled trial.
Topics: 4-Aminopyridine; Animals; Demyelinating Diseases; Dogs; Double-Blind Method; Female; Gait; Hindlimb; | 2014 |
Treatment of stable chronic demyelinating polyneuropathy with 3,4-diaminopyridine.
Topics: 4-Aminopyridine; Action Potentials; Adult; Aged; Aged, 80 and over; Amifampridine; Charcot-Marie-Too | 1995 |
16 other studies available for 4-aminopyridine and Demyelinating Diseases
| Article | Year |
|---|---|
A Rational Design of a Selective Inhibitor for Kv1.1 Channels Prevalent in Demyelinated Nerves That Improves Their Impaired Axonal Conduction.
Topics: Animals; Cell Line; Corpus Callosum; Demyelinating Diseases; Drug Design; Humans; Kv1.1 Potassium Ch | 2017 |
Radiochemical Synthesis and Evaluation of 3-[
Topics: 4-Aminopyridine; Animals; Blood-Brain Barrier; Brain; Demyelinating Diseases; Kv1.1 Potassium Channe | 2022 |
Radiochemical Synthesis and Evaluation of 3-[
Topics: 4-Aminopyridine; Animals; Blood-Brain Barrier; Brain; Demyelinating Diseases; Kv1.1 Potassium Channe | 2022 |
Radiochemical Synthesis and Evaluation of 3-[
Topics: 4-Aminopyridine; Animals; Blood-Brain Barrier; Brain; Demyelinating Diseases; Kv1.1 Potassium Channe | 2022 |
Radiochemical Synthesis and Evaluation of 3-[
Topics: 4-Aminopyridine; Animals; Blood-Brain Barrier; Brain; Demyelinating Diseases; Kv1.1 Potassium Channe | 2022 |
Radiochemical Synthesis and Evaluation of 3-[
Topics: 4-Aminopyridine; Animals; Blood-Brain Barrier; Brain; Demyelinating Diseases; Kv1.1 Potassium Channe | 2022 |
Radiochemical Synthesis and Evaluation of 3-[
Topics: 4-Aminopyridine; Animals; Blood-Brain Barrier; Brain; Demyelinating Diseases; Kv1.1 Potassium Channe | 2022 |
Radiochemical Synthesis and Evaluation of 3-[
Topics: 4-Aminopyridine; Animals; Blood-Brain Barrier; Brain; Demyelinating Diseases; Kv1.1 Potassium Channe | 2022 |
Radiochemical Synthesis and Evaluation of 3-[
Topics: 4-Aminopyridine; Animals; Blood-Brain Barrier; Brain; Demyelinating Diseases; Kv1.1 Potassium Channe | 2022 |
Radiochemical Synthesis and Evaluation of 3-[
Topics: 4-Aminopyridine; Animals; Blood-Brain Barrier; Brain; Demyelinating Diseases; Kv1.1 Potassium Channe | 2022 |
Neuroprotective effect of newly synthesized 4-aminopyridine derivatives on cuprizone-induced demyelination in mice-a behavioral and immunohistochemical study.
Topics: 4-Aminopyridine; Animals; Behavior, Animal; Cuprizone; Demyelinating Diseases; Immunohistochemistry; | 2021 |
Development of a PET radioligand for potassium channels to image CNS demyelination.
Topics: 4-Aminopyridine; Animals; Demyelinating Diseases; Female; Fluorine Radioisotopes; Humans; Macaca mul | 2018 |
Compression induces acute demyelination and potassium channel exposure in spinal cord.
Topics: 4-Aminopyridine; Action Potentials; Analysis of Variance; Animals; Demyelinating Diseases; Electroph | 2010 |
K+ channel blockade impairs remyelination in the cuprizone model.
Topics: 4-Aminopyridine; Animals; Astrocytes; Chelating Agents; Corpus Callosum; Cuprizone; Demyelinating Di | 2004 |
Conduction failure in demyelination: is it inevitable?
Topics: 4-Aminopyridine; Aminopyridines; Animals; Anura; Axons; Cats; Central Nervous System; Demyelinating | 1981 |
The use of potassium channel blocking agents in the therapy of demyelinating diseases.
Topics: 4-Aminopyridine; Amifampridine; Demyelinating Diseases; Humans; Potassium Channels | 1994 |
3,4-Diaminopyridine in demyelinating peripheral neuropathies.
Topics: 4-Aminopyridine; Amifampridine; Demyelinating Diseases; Humans; Neural Conduction; Potassium Channel | 1994 |
Failure of 3,4-diaminopyridine to reverse conduction block in inflammatory demyelinating neuropathies.
Topics: 4-Aminopyridine; Amifampridine; Chronic Disease; Demyelinating Diseases; Humans; Neural Conduction; | 1993 |
Slow sodium-dependent potential oscillations contribute to ectopic firing in mammalian demyelinated axons.
Topics: 4-Aminopyridine; Action Potentials; Animals; Axons; Demyelinating Diseases; Electrophysiology; Male; | 1997 |
Potassium channel distribution, clustering, and function in remyelinating rat axons.
Topics: 4-Aminopyridine; Action Potentials; Animals; Axons; Demyelinating Diseases; Electric Conductivity; E | 1998 |
Effects of 4-aminopyridine on demyelinated axons, synapses and muscle tension.
Topics: 4-Aminopyridine; Animals; Axons; Demyelinating Diseases; Male; Muscle Contraction; Muscle, Skeletal; | 2000 |
Ectopic activity in demyelinated spinal root axons of the rat.
Topics: 4-Aminopyridine; Action Potentials; Animals; Axons; Demyelinating Diseases; Electrophysiology; Femal | 1992 |
Effects of 4-aminopyridine in experimental CNS demyelination.
Topics: 4-Aminopyridine; Aminopyridines; Animals; Central Nervous System Diseases; Demyelinating Diseases; D | 1988 |
4-Aminopyridine leads to restoration of conduction in demyelinated rat sciatic nerve.
Topics: 4-Aminopyridine; Action Potentials; Aminopyridines; Animals; Demyelinating Diseases; Female; In Vitr | 1985 |